Business Context and Reporting Period
This Form 8-K Current Report was filed by Capricor Therapeutics, Inc. on August 19, 2020. The report discloses material events occurring on August 19 and August 20, 2020, involving a subsidiary agreement and corporate governance amendments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on legal and operational agreements rather than financial performance data.
Material Changes and Agreements
Amendment to Exclusive License Agreement
On August 19, 2020, Capricor, Inc. (a wholly-owned subsidiary) and Cedars-Sinai Medical Center (CSMC) entered into the Seventh Amendment to their Exclusive License Agreement regarding exosomes. Key terms include:
- Performance Milestones: Capricor must satisfy specific milestones for future patent rights to maintain exclusivity. Failure to meet these may result in the license converting to non-exclusive or co-exclusive, or termination.
- Milestone Confirmation: CSMC acknowledged that Capricor has already satisfied milestones for certain existing patent families, maintaining exclusivity for those rights.
- Patent Filings: The parties agreed to update inventor listings in future filings and grant Capricor an exclusive license to CSMC's interest therein.
Amendments to Bylaws
On August 20, 2020, the Board amended the Company's Bylaws to add Article IX, establishing exclusive forum selection provisions:
- Delaware Courts: Derivative actions, fiduciary duty claims, and internal affairs claims must be heard exclusively in the Court of Chancery of the State of Delaware or the federal district court of Delaware.
- Federal Courts: Claims under the Securities Act of 1933 must be heard exclusively in the federal district courts of the United States.
Guidance, Outlook, and Risks
The filing does not contain financial guidance or management commentary on future outlook. The primary risk disclosed relates to the potential loss of exclusive licensing rights for future patent families if performance milestones are not met. Additionally, the new bylaw amendments restrict the venues for legal disputes, which may impact litigation strategies.
Investor Verification Checklist
- Verify the specific performance milestones required to maintain exclusivity for future patent rights under the Seventh Amendment.
- Confirm the status of the confidential treatment request for specific terms of the Seventh Amendment.
- Review the full text of the Amended and Restated Bylaws (Exhibit 3.1) to understand the scope of the forum selection clauses.
- Monitor future filings for the formal inclusion of the Seventh Amendment as an exhibit.